Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | 4.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 1.93 | - |
NAV | ₹39.10 | - |
Fund Started | 12 Nov 2018 | - |
Fund Size | ₹3178.53 Cr | - |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | - |
Risk
Very High
-
Rating
4.0
-
Min SIP Amount
₹100
-
Expense Ratio
1.93
-
NAV
₹39.10
-
Fund Started
12 Nov 2018
-
Fund Size
₹3178.53 Cr
-
Exit Load
Exit load of 0.50% if redeemed within 1 month.
-
Returns
1 Year | -5.23% | - |
3 Year | 21.16% | - |
5 Year | 15.60% | - |
1 Year
-5.23%
-
3 Year
21.16%
-
5 Year
15.60%
-
Holding Analysis
Equity | 97.09% | - |
Cash | 2.91% | - |
Equity
97.09%
-
Cash
2.91%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 8.85% |
Cipla Ltd. | 8.63% |
Ipca Laboratories Ltd. | 7.76% |
Globus Medical Inc | 6.89% |
Laurus Labs Ltd. | 6.21% |
Illumina Inc. (USA) | 5.93% |
Cohance Lifesciences Ltd. | 5.27% |
Gland Pharma Ltd. | 5.10% |
Sai Life Sciences Ltd. | 4.99% |
Apollo Hospitals Enterprise Ltd. | 4.49% |
-
Fund Manager
Name | Jay Kothari | - |
Start Date | 07 Mar 2024 | - |
Name
Jay Kothari
-
Start Date
07 Mar 2024
-
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | - |
Launch Date | 12 Nov 2018 | - |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
-
Launch Date
12 Nov 2018
-